ARCTURUS THERAPEUTICS HOLDINGS INC. Deferred Revenue Recognized
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Deferred Revenue Recognized of -$5.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was -$2.06M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was -$29.38M, a 177.30% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $38.01M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$80.28M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for fiscal 2025 was -$81.69M, a 409.45% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for fiscal 2024 was $26.40M, a 57.83% decline from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for fiscal 2023 was $62.60M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. contract with customer, liability, revenue recognized for fiscal 2022 was -$217.77M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$5.02M 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | -$2.06M 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | -$81.69M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | -$74.83M 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | -$57.68M 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | -$29.38M 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $26.40M 10-K · filed 2026-03-03 | -$152.81M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$129.54M 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | -$87.87M 10-Q · filed 2024-08-05 | ||||
| 2024-03-31 | $38.01M 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $62.60M 10-K · filed 2025-03-06 | -$166.80M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | -$135.94M 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | -$90.80M 10-Q · filed 2023-08-07 | ||||
| 2023-03-31 | -$80.28M 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | -$217.77M 10-K · filed 2023-03-29 | ||||
| 2022-09-30 | -$45.71M 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | -$32.34M 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | -$5.24M 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | -$12.36M 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | -$6.57M 10-Q · filed 2021-11-09 | ||||
| 2021-06-30 | -$4.13M 10-Q · filed 2021-08-10 | ||||
| 2021-03-31 | -$2.13M 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | -$9.54M 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $7.30M 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $4.97M 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | -$2.65M 10-Q · filed 2020-05-08 | ||||
| 2019-12-31 | -$21.16M 10-K · filed 2020-03-16 | ||||
| 2019-09-30 | -$18.20M 10-Q · filed 2019-11-08 | ||||
| 2019-06-30 | -$14.88M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |